Breaking News

Onyx Expands UK Site

January 29, 2016

Expansion comes on the heels of a record growth year for the CRO

Onyx Scientific is set to increase the size of its UK-based site by over 30pc following the best performance in the company’s 15 year history. The contract research organization (CRO) and small-scale API manufacturer is investing in an additional site located adjacent to its existing facility in Northeast England to help its clients accelerate candidates from discovery to production.

The additional space will be used to increase its laboratory facilities, GMP suites and allocate space for storage of GMP materials. As part of the expansion initiative, Onyx has recruited several more chemists to support clients’ pre-clinical, development and early stage API manufacturing projects.

“It’s been a challenging few years for CROs across the industry but our team has continued to work hard to always exceed clients’ expectations, which has led to a very loyal customer base and regular repeat business,” said Denise Bowser, commercial director, Onyx Scientific. “Although we have come to the end of a very positive year, we have never been a firm to rest on our laurels. With the support of our parent company Ipca Laboratories, we are very much investing in our physical capacity, equipment and technical resource.

This latest venture follows investment last year to grow its GMP space following an increase in demand for its small scale API manufacturing services.

Established back in 2000, Onyx Scientific now provides clients with the production of API in up to 50l-100l equipment under current GMP regulations, which fits with its earlier stage custom synthesis, lead optimization and analytical services.

“The decision to expand into an additional building has been driven by increased demand for GMP services as well as continuous flow projects and solid state chemistry, which has fully utilized our resources over the past 12 months,” said Ms. Bowser.
blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • 2015 Contracting & Outsourcing Wrap-up

    2015 Contracting & Outsourcing Wrap-up

    Kristin Brooks, Contract Pharma||September 30, 2015
    A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Robust Assay Designs

    Robust Assay Designs

    Tim Wright, Editor, Contract Pharma||October 11, 2016
    Easing the transition from preclinical to clinical research

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent